Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 1/2 3Phase 3 2Phase 1 2Phase 2/3 1

Status

Completed 31Terminated 11Withdrawn 4Active not recruiting 2Unknown 1Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Hematologic Neoplasms 1

Interventions

pembrolizumab 86Cyclophosphamide 75Nivolumab 55Specimen Handling 49fludarabine 48Magnetic Resonance Spectroscopy 44Carboplatin 41Biopsy 39Radiotherapy 32fludarabine phosphate 29Gemcitabine 28venetoclax 27atezolizumab 26Paclitaxel 26Ipilimumab 26Radiation 22Dexamethasone 22Cisplatin 22Radiosurgery 21durvalumab 20Rituximab 20Lenalidomide 19Temozolomide 17Bevacizumab 17Pemetrexed 15Decitabine 15Cytarabine 15130-nm albumin-bound paclitaxel 15palbociclib 14ibrutinib 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Active not recruiting × Busulfan × Clear all
NCT03613532 2026-05-20

Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN

Dana-Farber Cancer Institute

Phase 1 Active not recruiting
102 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT04098393 2025-06-29

Giving Chemotherapy for a Shortened Amount of Time Before a Stem Cell Transplantation

Memorial Sloan Kettering Cancer Center

Phase 1 Active not recruiting
39 enrolled
Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡